Beckman Coulter nabs EUA for COVID-19 IgM assay

By staff writers

October 9, 2020 -- The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Beckman Coulter's Access SARS-CoV-2 immunoglobulin M (IgM) assay, which detects antibodies that recognize the receptor-binding domain (RBD) of the spike protein on the virus.

The Access SARS-CoV-2 IgM assay has 99.9% specificity and 98.3% sensitivity, according to Beckman Coulter.

The firm is also developing a SARS CoV-2 antigen assay as well as a quantitative IgG assay that it anticipates will be launched later this year.

FDA grants Beckman Coulter EUA for assay test
The U.S. Food and Drug Administration (FDA) has awarded Beckman Coulter emergency use authorization (EUA) for its Access Interleukin-6 assay.
Beckman Coulter releases COVID-19 antibody test
Beckman Coulter has released its Access SARS-CoV-2 Immunoglobulin M assay, a new antibody test for the novel coronavirus. The assay targets antibodies...
FDA clears Beckman Coulter's automated microplate system for blood banking
Beckman Coulter has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its automated microplate system and associated reagents.
Beckman Coulter secures EUA for SARS-CoV-2 test
Beckman Coulter has secured an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its SARS-CoV-2 immunoglobulin G antibody...
Beckman Coulter's SARS-CoV-2 IgG assay hits CE Mark countries
Beckman Coulter announced its Access SARS-CoV-2 immunoglobulin G (IgG) assay is now available in markets that accept the CE Mark.

Copyright © 2020

Last Updated ls 10/9/2020 3:48:02 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current